SCHEMBL25056409

SCHEMBL25056409

COc1cc2c(cc1N)-c1cnn(C)c1CCC2O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK1 P53350 1/20 0.33
▸ CSNK2A1 P68400 1/20 0.33
▸ PLK3 Q9H4B4 1/20 0.33
▸ POLL Q9UGP5 1/20 0.32
▸ CYP11B1 P15538 1/20 0.32
▸ CYP11B2 P19099 1/20 0.32
▸ TUBB4A P04350 3/20 0.31
▸ TUBB P07437 3/20 0.31
▸ TUBA3C P0DPH7 3/20 0.31
▸ TUBA1B P68363 3/20 0.31
▸ TUBA4A P68366 3/20 0.31
▸ TUBB4B P68371 3/20 0.31
▸ TUBB3 Q13509 3/20 0.31
▸ TUBB2A Q13885 3/20 0.31
▸ TUBB8 Q3ZCM7 3/20 0.31
▸ TUBA3E Q6PEY2 3/20 0.31
▸ TUBA1A Q71U36 3/20 0.31
▸ TUBA1C Q9BQE3 3/20 0.31
▸ TUBB6 Q9BUF5 3/20 0.31
▸ TUBB2B Q9BVA1 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25056248 0.86 PLK1 (0.33) PLK1CSNK2A1PLK3CYP11B1CYP11B2
SCHEMBL25637752 0.81 PKM (0.37) POLL
SCHEMBL25056325 0.78 DDB1 (0.36) PLK1CSNK2A1PLK3ACHE
SCHEMBL25056306 0.77 PLK1 (0.48) PLK1CSNK2A1PLK3CYP11B1CYP11B2
SCHEMBL25056298 0.76 CYP11B1 (0.33) CYP11B1CYP11B2CYP3A4S100BACHE
SCHEMBL25056352 0.76 PLK1 (0.35) PLK1CSNK2A1PLK3CYP11B1CYP11B2
SCHEMBL25056305 0.75 PLK1 (0.46) PLK1CSNK2A1PLK3CYP11B1CYP11B2
SCHEMBL25056405 0.74 KMT2A (0.33) PLK1CSNK2A1PLK3CYP11B1CYP11B2
SCHEMBL25056313 0.74 PLK1 (0.35) PLK1CSNK2A1PLK3CYP11B1CYP11B2
SCHEMBL25056148 0.74 CYP11B1 (0.36) PLK1CSNK2A1PLK3CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS QILU PHARMACEUTICAL CO LTD (CN) 2023-06-22 — — US disclosed
EP-4137484-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS QILU PHARMACEUTICAL CO., LTD. (CN) 2023-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS EGFR, ERBB2, ERBB3 PLK1 76/4885CSNK2A1 215/4885PLK3 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback